Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 plus adebrelimab and platinum-based chemotherapy as first-line treatment for advanced gastric and esophageal cancer
CTR20240377Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Mar 2024; status: active.
02
Drugs
CS1002
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20240377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240377.